When it comes to certain cancers, the answers to a patient’s diagnosis and treatment plan can start at the microscopic level. Chromosome analysis through cytogenetic karyotyping is an essential part of some cancer patients' journeys, as the chromosomal changes seen under a microscope help inform the patient's diagnosis, prognosis and help direct personalized treatment planning. A successful karyotype depends on the ability to grow or “culture" patient cells in media, typically from blood or bone marrow. If the culture fails to grow, it can leave clinicians without the critical information they need to direct patient care.
Recognizing the importance of this step, the Clinical Genetics Laboratory, located at the Juravinski Hospital at Hamilton Health Sciences, diligently monitors cytogenetic culture failure rates as part of its quality performance indicators. The Genetics Quality Leadership Team is a group led by the manager, front-line laboratory staff and laboratory scientists who meet regularly to identify and review indicators that measure the performance using a Continuous Quality Improvement (CQI) Scorecard.
During one such review, an upward trend in the percentage of cytogenetic cancer culture failures was observed. In a six-month period, the percent of cancer karyotype reports issued with failed or incomplete results climbed from 4% of cases per month to 18%; this observation prompted an in-depth investigation into the root cause.

The Genetics laboratory assembled a small team including frontline Medical Laboratory Technologists (MLTs), Technical Specialists and the Laboratory Genetic Counsellor to discuss potential causes of the increase in culture failure. Several potential root causes were discussed, however the frontline laboratory staff had a strong theory that the culture failures were related to blood samples received in the incorrect anti-coagulant vacutainer, as certain additives in blood draw tubes can have a negative effect on the growth of blood cells in culture.
Leveraging data within the hospital's Electronic Medical records (EMR) and through manual tracking on the lab bench, the team was able to determine that there had been an increase in the number of blood specimens received in EDTA anti-coagulant (purple top), rather than the preferred additive Sodium Heparin (green top). In fact, the data showed a 97% percent failure rate for leukemic blood samples received in EDTA purple top tubes. The impact of this was two-fold; patients weren't getting the results they needed and the laboratory was wasting resources setting up samples that were unlikely to be successfully grown in culture.
With this data in hand, two corrective actions were agreed upon in consultation with Genetics' Laboratory Scientists and Laboratory Genetic Counsellor. First, the laboratory's specimen acceptance and rejection criteria was revised such that if a leukemic blood was received in an EDTA tube, it would not be set-up for cytogenetic analysis. This would reduce waste associated with reagents and technologist time for culturing and attempting to analyze samples that were unlikely to produce results of sufficient quality. Secondly, a memo was distributed to internal and external clients to communicate the change in rejection criteria and to provide education that the preferred sample type for all cytogenetic analysis is sodium heparin, as indicated on the laboratory requisition and within the EMR system.
On-going monitoring of culture failure via the Genetics Quality Leadership Team has demonstrated that these corrective actions have been successful, with a reduction in culture failures from a peak of 18% back to a reasonable baseline of 4-6% in the three months post-implementation.
This quality improvement highlights the benefits of utilizing a CQI scorecard, a tool in the Hamilton Health Science's Continuous Quality Improvement (CQI) management system and ensuring that the voice of frontline staff is considered during root cause analysis.